natgillin/translations-raw huggingface dataset:
During post-marketing use in this age group, cases of hallucinations (associated with anxiety manifestations) and sleep disorders correlated with oxybutynin have been reported.
V obdobju trženja so pri tej starostni skupini poročali o primerih halucinacij (povezanih s pojavom tesnobe) in motenj spanja, ki so bili v korelaciji z oksibutininom.
Contains 1 transdermal patch.
Vsebuje 1 transdermalni obliž.
The transdermal patches are individually contained in LDPE/paper laminate sachets and supplied in Patient Calendar Boxes of 2, 8 or 24 patches.
Transdermalni obliži so posamično pakirani v LDPE/papirnate laminatne vrečke in zloženi v škatlice s koledarji s po 2, 8 ali 24 obližev.
The other ingredients are: Each patch contains triacetin, and acrylic adhesive solution.
Pomožne snovi so: En obliž vsebuje triacetin in raztopino akrilnega adheziva.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON (Containing 2, 8 and 24 transdermal patches)
PODATKI NA ZUNANJI OVOJNINI ŠKATLA (vsebuje 2, 8 in 24 transdermalnih obližev)
If you are a woman of childbearing age, you should be tested for pregnancy before using Kentera.
Če ste ženska v rodni dobi, morate pred uporabo zdravila Kentera opraviti preizkus nosečnosti.
- Press the entire patch firmly onto the skin with your fingertips.
- Obliž trdno pritisnite na kožo s konicami prstov.
Also in conditions such as ulcerative colitis, and intestinal atony.
Enako velja za bolezni, kot sta ulcerozni kolitis in intestinalna atonija.
This leaflet was approved in
Navodilo je bilo odobreno
The oxybutynin, triacetin and acrylic adhesive are coated on clear PET/EVA backing film and covered with a siliconised polyester release liner.
Oksibutinin, triacetin in akrilno lepilo so naneseni na prozorno zaščitno folijo iz PET/EVA in prekriti s silikonizirano plastjo za sproščanje iz poliestra.
- Without touching the sticky surface, firmly press the patch, adhesive face down, onto the part of the abdomen, hips or buttocks you have selected for application.
- Brez da se dotaknete lepljive površine, nežno stisnite obliž z lepljivim delom navzdol na del trebuha, bokov ali zadnjice, kamor želite obliž nalepiti.
Anticholinergic medicinal products should be used with caution in patients who have autonomic neuropathy, cognitive impairment or Parkinson's disease.
Antiholinergična zdravila je treba uporabljati previdno pri bolnikih z avtonomno nevropatijo, kognitivno okvaro ali Parkinsonovo boleznijo.
A total of 957 patients with urge urinary incontinence were evaluated in three controlled studies comparing Kentera to either placebo, oral oxybutynin and/or tolterodine long acting capsules.
V treh kontroliranih študijah je sodelovalo skupaj 957 bolnikov z urgentno urinarno inkontinenco v primerjavi zdravila Kentera s placebom, peroralnim oksibutininom in/ali kapsulami tolterodina s podaljšanim sproščanjem.
If prime is lost during the use (no gel is dispensed after depressing the pump), repeat as instructed above to re-prime the pump.
Če se med uporabo črpalka izprazni (črpalka po pritisku ne iztisne gela), jo znova napolnite skladno z navodili zgoraj.
A small amount of orally administered oxybutynin is excreted in the mother's milk.
Majhna količina peroralno uporabljenega oksibutinina se izloča v materino mleko.
Oxybutynin administered orally is metabolised primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall.
Peroralno zaužit oksibutunin v glavnem presnavljajo citokromski encimski sistemi P450, še posebej CYP3A4, ki ga najdemo v glavnem v jetrih in steni drobovja.
Rotating approved application sites with each dose may help in reducing the risk of developing skin irritations.
S spreminjanjem primernih mest nanašanja pri vsakem odmerku se zmanjša nevarnost draženja kože.
Patients on Kentera therapy should keep application sites covered with clothing when coming into contact with breast-feeding or pregnant women or breast-fed infants.
Bolniki, ki uporabljajo zdravilo Kentera, naj mesto uporabe prekrijejo z oblačili, kadar so v stiku z doječimi ženskami ali nosečnicami ali z novorojenčki, ki se hranijo z dojenjem.
Apply a new Kentera patch twice weekly (every 3 to 4 days).
Nov obliž zdravila Kentera namestite dvakrat tedensko (vsake 3 do 4 dni).
The volume of distribution was estimated to be 193 l after intravenous administration of 5 mg oxybutynin hydrochloride.
Ocenjen volumen porazdelitve je 193 l po intravenskem odmerjanju 5 mg oksibutininijevega klorida.
Headache, somnolence
- glavobol ali zaspanost
Travel subscale
Podlestvica potovanje
Following the application of Kentera, oxybutynin plasma concentration increases for approximately 24 to 48 hours, reaching average maximum concentrations of 3 to 4 ng/ml.
Po nanosu obliža Kentera naraste koncentracija oksibutinina v plazmi za približno 24 do 48 ur in doseže povprečno maksimalno koncentracijo od 3 do 4 ng/ml.
HOW TO USE KENTERA
KAKO UPORABLJATI ZDRAVILO KENTERA
Anticholinergic medicinal products should be used with caution in patients who have hiatus hernia/gastro-oesophageal reflux and/or who are concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate oesophagitis.
Antiholinergična zdravila je treba pazljivo uporabljati pri bolnikih, ki imajo hiatusno kilo/gastro-ezofagealni refluks in/ali trenutno jemljejo zdravila (kot so bisfosfonati), ki lahko povzročijo ali poslabšajo ezofagitis.
Do not apply Kentera in an area that is not approved.
Zdravila Kentera ne nanašajte na površino, ki ni primerna.
Fertility studies in rats suggest a 6 fold margin of safety in both male and female breeding adults when Kentera is administered as prescribed (see section 5.3).
Študije plodnosti pri podganah so pokazale 6-kratno varnostno mejo pri razmnožujočih se odraslih samcih in samicah, kadar se zdravilo Kentera uporablja skladno z navodilom (glejte poglavje 5.3).
6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi
Thus based on current clinical evidence no need for dose adjustment in elderly patients is considered necessary.
Zato velja, da na podlagi trenutnih kliničnih dokazov odmerka ni treba prilagajati.
- Dipyridamole (used to treat blood clotting problems).
- Dipiridamol (uporablja se za zdravljenje težav s strjevanjem krvi).
Only apply Kentera to intact skin.
Zdravilo Kentera nanesite samo na nepoškodovano kožo.
Be sure all of it sticks to your skin, even around the edges.
Prepričajte se, da je obliž v celoti nalepljen na kožo, tudi ob robovih.
Step 2: Open the sachet that contains the patch.
2. korak: Odprite vrečko z obližem.
In the subcutaneous fertility study in rats, while no effects were reported in males, in females, fertility was impaired and a NOAEL (no observed adverse effect level) of 5 mg/kg was identified.
V študijah subkutane plodnosti na podganah ni bilo učinkov na samce, medtem ko so pri samicah opažali zmanjšano plodnost in določili stopnjo NOAEL (stopnja, pri kateri ni opaženih neželenih učinkov) 5 mg/kg.
Kentera may produce drowsiness, sleepiness, or blurred vision.
Zdravilo Kentera lahko povzroči dremavost, zaspanost ali zamegljen vid.
Pharmacovigilance System:
Sistem farmakovigilance
The effect of showering on the absorption of oxybutynin was evaluated in a randomised, steady-state crossover study under conditions of no shower, or showering 1, 2 or 6 hours after Kentera application (N=20).
Vpliv prhanja na absorpcijo oksibutinina so ocenili v randomizirani navzkrižni študiji dinamičnega ravnovesja, pod naslednjimi pogoji: brez prhanja ali s prhanjem 1, 2 ali 6 ur po aplikaciji zdravila Kentera (N = 20).
Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
Manj kot 0,1 % odmerka se izloči kot metabolit N-dezetiloksibutinin.
The free base form of oxybutynin is pharmacologically equivalent to oxybutynin hydrochloride.
Prostobazna oblika oksibutinina je farmakološko ekvivalentna oksibutininijevemu kloridu.
Apply the patch to a clean, dry, smooth area of skin on your abdomen, hips or buttocks.
Obliž nanesite na čist, suh, gladek predel kože na trebuhu, bokih ali zadnjici.
Pharmacotherapeutic group: Urologicals, urinary antispasmodics, ATC code: G04B D04.
Farmakoterapevtska skupina: urospazmolitiki, oznaka ATC: G04B D04.
Other commonly occurring adverse drug reactions reported were dry mouth (8.6%), constipation (3.9%), diarrhoea (3.2%), headache (3.0%), dizziness (2.3%) and blurred vision (2.3%).
(3,9 %), driska (3,2 %), glavobol (3,0 %), omotičnost (2,3 %) in zamegljen vid (2,3 %).
Take special care with Kentera:
Bodite posebno pozorni pri uporabi obližev Kentera:
Oxybutynin may antagonize prokinetic therapies.
Oksibutinin lahko nevtralizira vpliv prokinetske terapije.
- If you have further questions, please ask your doctor or your pharmacist.
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
Mechanism of action: oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle.
Mehanizem delovanja: oksibutinin deluje kot kompetitivni antagonist acetilholina na postganglijske muskarinske receptorje, ki povzročijo sprostitev gladkih mišic mehurja.
Oxybutynin may antagonise prokinetic therapies, such as cisapride and metocloparamide, and should be avoided in the presence of reduced gastrointestinal motility conditions.
Oksibutinin ima lahko antagonističen učinek na prokinetike, kot sta cisaprid in metoklopramid, zato se mu je treba pri zmanjšani gastrointestinalni motiliteti izogibati.
Pharmacodynamic effects:
Farmakodinamični učinek:
Each multidose container contains at least 30 grams of Kentera and dispenses 30 metered 1 gram doses.
En večodmerni vsebnik vsebuje najmanj 30 gramov zdravila Kentera in dovaja 30 odmerjenih enogramskih odmerkov.
Before using the pump for the first time the multidose container should be primed.
Pred prvo uporabo je treba večodmerni vsebnik napolniti.
Backing: polyester/ethylene-vinyl acetate film; siliconised polyester film.
Hrbtna plast: poliester/plast iz etilen-vinil acetata; silikonizirana poliesterska plast.
Oxybutynin is transported across intact skin and into the systemic circulation by passive diffusion across the stratum corneum.
Oksibutinin se v sistemski obtok transportira skozi nepoškodovano kožo s pasivno difuzijo skozi stratum corneum.
Carefully throw away the open sachet so that children and pets are not exposed to it.
Previdno zavrzite odprto vrečico, da otroci ali hišni ljubljenčki ne pridejo v stik z njo.
Kentera is a transdermal patch and it is packaged in cartons containing 2, 8, and 24 patches.
Zdravilo Kentera je transdermalni obliž, pakirano pa je v škatle, ki vsebujejo 2, 8 ali 24 obližev.
MedDRA System Organ Class
Po MedDRA Organski sistem
The sachet is constructed from a multi-layer foil based laminate pouch material (polymethacrylate/acrylonitrile copolymer/adhesive/aluminum/low density polyethylene/paper).
Vrečica je izdelana iz večplastne folije (kopolimer polimetakrilata in akrilonitrila/lepilo/aluminij/polietilen majhne gostote/papir).
Printed on the inside flap of your Kentera package, you will find a Kentera calendar checklist that will help you to remember your dosing schedule.
Na notranji strani škatlice Kentera je natisnjen koledarček s kontrolnim seznamom za lažji nadzor urnika nanašanja.
This should be borne in mind when using azole antifungals (e.g. ketoconasole) or macrolide antibiotics (e.g. erythromycin) concurrently with oxybutynin.
To je treba upoštevati pri sočasni uporabi azolnih antimikotikov (npr. ketokonazola) ali makrolidnih antibiotikov (npr. eritromicina) z oksibutininom.
Avoid bathing, swimming, showering, exercising or immersing the application site in water for one hour after application (see section 4.4).
Eno uro po uporabi se izogibajte kopanju, plavanju, prhanju, telesni vadbi ali potapljanju mesta nanosa v vodo (glejte poglavje 4.4).
EU/1/03/270/004 <30 sachets>
EU/1/03/270/004 <30 vrečic>
The sachet is constructed from a multi-layer foil based laminated pouch material.
Vrečica je izdelana iz večplastne folije.
Oxybutynin may lead to suppressed salivary secretions which could result in dental caries, parodontosis or oral candidiasis.
Oksibutinin lahko zavre izločanje sline, kar lahko povzroči zobni karies, parodontozo ali oralno kandidozo.
The approved application sites for Kentera are the shaded areas shown in Figure A. These are the abdomen (stomach area), upper arms/shoulder, and thigh.
1. korak: Primerna mesta uporabe zdravila Kentera so zasenčene površine, prikazane na sliki A. To so trebuh, nadlakti/ramena in stegna.
The potential for dermal transfer of oxybutynin from a treated person to an untreated person was evaluated in a single-dose study where subjects dosed with Kentera engaged in vigorous contact with an untreated partner for 15 minutes, either with (N=14 couples) or without (N=12 couples) clothing covering the application area.
Možnost prenosa oksibutinina prek kože z zdravljene na nezdravljeno osebo so ocenili v študiji z enkratnim odmerkom, v kateri so bili preizkušanci, ki so prejeli zdravilo Kentera, 15 minut v aktivnem stiku z nezdravljenim partnerjem, z oblačili, ki so prekrivala mesto aplikacije (N = 14 parov) ali brez njih (N = 12 parov).
- The other ingredients are: ethanol (96%), glycerol, hydroxypropylcellulose, sodium hydroxide (for pH adjustment), and purified water.
- Pomožne snovi so: etanol (96-odstotni), glicerol, hidroksipropilceluloza, natrijev hidroksid (za uravnavanje pH) in prečiščena voda.
As oxybutynin is metabolised by cytochrome P 450 isoenzyme CYP 3A4, interactions with medicinal products that inhibit this isoenzyme cannot be ruled out.
Ker oksibutinin presnavlja citokromski P 450 izoencim CYP 3A4, medsebojnega delovanja z zdravili, ki inhibirajo ta izoencim, ni mogoče izključiti.
The usual dose is one sachet applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs, which delivers 4 mg of oxybutynin in 24 hours.
nanesena enkrat na dan na suho, nepoškodovano kožo trebuha, nadlakti/ramen ali stegen, ki dovaja 4 mg oksibutinina v 24 urah.
Apply immediately after opening the sachet.
Uporabite takoj po odprtju vrečice.
- Phenothiazines or clozapine (used to treat mental illness).
- Fenotiazini ali klozapin (uporabljajo se za zdravljenje duševnih bolezni).
- Free of cuts, rashes or any other skin irritation.
- Na katerem nimate ureznin, izpuščajev ali kako drugače razdražene kože.
Always use Kentera exactly as your doctor has instructed you.
Zdravila Kentera vedno uporabljajte natančno po navodilih zdravnika.
See Figure C.
Glejte sliko C.
You should not apply more than a single metered dose during a 24 hour period.
Če ste uporabili večji odmerek zdravila Kentera, kot bi smeli V 24-urnem obdobju ne smete nanesti več kot en odmerjeni odmerek.
Excipients: ethanol (96%), glycerol, hydroxypropylcellulose, sodium hydroxide (for pH adjustment), and purified water.
Pomožne snovi: etanol (96-odstotni), glicerol, hidroksipropilceluloza, natrijev hidroksid (za uravnavanje pH) in prečiščena voda.
Oxybutynin is extensively metabolised by the liver, see above with less than 0.1% of the administered dose excreted unchanged in the urine.
Oksibutinin v veliki meri presnovijo jetra, manj kot 0,1 % odmerka se je izločilo z urinom v nespremenjeni obliki.
EU/1/03/270/005 <1 multidose container with metering pump>
EU/1/03/270/005 <1 večodmerni vsebnik z odmerno črpalko>
What Kentera is and what it is used for Before you use Kentera How to use Kentera Possible side effects How to store Kentera Further Information
Kaj je zdravilo Kentera in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Kentera Kako uporabljati zdravilo Kentera
The patch is a clear plastic with an adhesive backing, protected by a release liner that is to be removed prior to application.
Obliž je iz prozorne plastike z lepljivo zadnjo stranjo, zaščiten s plastjo, ki se pred uporabo odstrani.
Patients treated with Kentera experienced a highly statistically significant decrease in the number of urinary incontinence episodes per day from baseline to endpoint (the primary efficacy endpoint) compared with placebo (p<0.0001), as well as for the secondary endpoints: a decrease in the average daily urinary frequency (p=0.0017), and an increase in the average urine volume per void (p=0.0018).
Pri bolnikih, ki so prejemali zdravilo Kentera, se je število epizod urinarne inkontinence na dan statistično značilno zmanjšalo od izhodiščne točke do konca študije (primarni opazovani dogodek učinkovitosti) v primerjavi s placebom (p < 0,0001), enako pa velja tudi za sekundarna opazovana dogodka študije:
- Free of body powder, lotion, and oil.
- Na katerem nimate pudra, kreme ali olja.
The recommended dose is one metered dose from the multidose container with metering pump applied once daily which corresponds to a delivery dose of approximately 4 mg.
Priporočeni odmerek je en odmerjen odmerek iz večodmernega vsebnika z odmerno črpalko, uporabljen enkrat na dan, kar ustreza dovajanemu odmerku približno 4 mg. Starejša populacija
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.
Simptomatsko zdravljenje urgentne inkontinence in/ali povečane pogostnosti in nujnosti uriniranja, ki se lahko pojavita pri odraslih bolnikih z nestabilnim sečnim mehurjem.
Other psychiatric events implying an anticholinergic mechanism have been reported during postmarketing use (see section 4.8).
Med obdobjem trženja so poročali tudi o drugih psihiatričnih dogodkih, ki kažejo na antiholinergični mehanizem (glejte poglavje 4.8).
Kentera contains the active substance oxybutynin and is used in adults to control the symptoms of urge incontinence and/or increased urinary frequency and urgency.
Zdravilo Kentera vsebuje zdravilno učinkovino oksibutinin, uporablja pa se pri odraslih za nadzor simptomov urgentne inkontinence in/ali povečane pogostnosti uriniranja in nuje po uriniranju.
Always place the small protective cap back firmly on the tip of the pump nozzle and the large pump cover over the top of the pump after each use.
Po vsaki uporabi vedno namestite zaščitno zaporko nazaj na konico šobe črpalke in veliki pokrov čez zgornji del črpalke.
Step 3.
3. faze.
The active metabolite, N-desethyloxybutynin, has pharmacological activity on the human detrusor muscle that is similar to that of oxybutynin in vitro studies, but has a greater binding affinity for parotid tissue than oxybutynin.
Aktivni presnovek N-dezetiloksibutinin farmakološko deluje na detruzorsko mišico pri človeku podobno kot oksibutinin v študijah in vitro, vendar ima večjo afiniteto za vezavo na parotidno tkivo kot oksibutinin.
Ingestion of 100 mg oral oxybutynin in association with alcohol has been reported in a 13 year old boy who experienced memory loss, and in a 34 year old woman who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine.
O zaužitju 100 mg oksibutinina po peroralni poti v povezavi z alkoholom so poročali pri 13-letnem dečku, pri katerem je prišlo do izgube spomina, in pri 34-letni ženski, pri kateri se je pojavil stupor, ki so mu sledili dezorientacija ter vznemirjenost ob bujenju, razširjene zenice, suha koža, srčna aritmija in retencija urina.
Apply immediately after dose delivered from the multidose container with metering pump.
Nanesite takoj po iztisku odmerka iz večodmernega vsebnika z odmerno črpalko.
- Antihistamines (used in the treatment of allergies such as hayfever).
- Antihistaminiki (uporabljajo se za zdravljenje alergij, kot je alergija na pelodni prah).
There are no adequate data on the use of oxybutynin topical gel in pregnant women.
Nosečnost Ni zadostnih podatkov o uporabi topičnega gela z oksibutininom pri nosečnicah.
Environmental Risk Assessment The active substance oxybutynin is persistent in the environment.
Zdravilna učinkovina oksibutinin je v okolju obstojna.
How to apply
Način uporabe
The multidose container is comprised of an outer bottle with a pouch liner, a metering pump and a cap.
Večodmerni vsebnik z odmerno črpalko je sestavljena iz zunanje steklenice s prevleko, odmerne črpalke in zaporke.
It is important you read and follow these directions on how to use the Kentera pump properly.
Kako uporabljati večodmerni vsebnik z odmerno črpalko: Pomembno je, da preberete in upoštevate ta navodila za pravilno uporabo črpalke Kentera.
Excipients: triacetin; acrylic adhesive (containing 2-ethylhexyl acrylate; N-vinyl pyrrolidone and hexamethyleneglycol dimethacrylate polymer domains).
Pomožne snovi: triacetín; akrilno lepilo (vsebuje 2-etilheksil akrilat N-vinil pirolidon in heksametileneglikol dimetakrilatni polimer).
Mean and median change from baseline in daily incontinence episodes (primary endpoint), urinary frequency, and urinary void volume between placebo and active treatment groups are summarised in the table below.
Povprečna in mediana sprememba dnevnih epizod inkontinence od izhodiščne točke (primarni opazovani dogodek), pogostnost uriniranja in prostornina izločenega urina pri skupini, ki je prejemala zdravilo, glede na skupino, ki je prejemala placebo, sta povzeti v preglednici spodaj.
Dry mouth, constipation
- suha usta - zaprtje - driska
Kentera transdermal patch:
Zdravilo Kentera transdermalni obliž:
If irritation persists, please contact your doctor.
Če se razdraženost kože ne pomiri, se posvetujte z zdravnikom.
Kentera is used in adults to control the symptoms of urge incontinence and/or increased urinary frequency and urgency.
Zdravilo Kentera se uporablja pri odraslih za nadzor simptomov urgentne inkontinence in/ali zvečane pogostnosti uriniranja in nuje po uriniranju.
The use of Kentera in patients with hepatic impairment should be carefully monitored since oxybutynin is extensively hepatic metabolised.
Bolnike z jetrno okvaro, ki uporabljajo zdravilo Kentera, je treba pozorno spremljati, saj se oksibutinin v veliki meri presnavlja v jetrih.
No cases of overdose have been reported with Kentera.
Primeri s prevelikim odmerjanjem zdravila Kentera niso znani.
A 14-week, open-label treatment was available for a subset of patients who completed the double-blind period.
Podskupina bolnikov, ki je končala dvojno slepo obdobje, je sodelovala v 14-tedenskem odprtem preskušanju.
The concomitant use of oxybutynin with other anticholinergic medicinal products or with other agents that compete for CYP3A4 enzyme metabolism may increase the frequency or severity of dry mouth, constipation, and drowsiness.
Sočasna uporaba oksibutinina in drugih antiholinergičnih zdravil, ali drugih zdravilnih učinkovin, ki tekmujejo za encim presnove CYP3A4, lahko poveča pogostnost ali resnost suhih ust, obstipacije in dremavosti.
Each transdermal patch contains 36 mg of oxybutynin.
En transdermalni obliž vsebuje 36 mg oksibutinina.
The difference in AUC and Cmax of oxybutynin and the active metabolite N-desethyloxybutynin following transdermal administration of Kentera on either the abdomen, upper arms/shoulders and thighs is not clinically relevant.
Razlika v vrednosti AUC in Cmax oksibutinina in njegovega aktivnega presnovka N-dezetiloksibutinina po transdermalni uporabi zdravila Kentera na trebuhu, nadlakteh/ramenih ali stegnih ni klinično pomembna.
The area of the patch is 39 cm2, releasing a nominal 3.9 mg of oxybutynin per 24 hours.
Površina obliža 39 cm2 sprošča nominalnih 3,9 mg oksibutinina na 24 ur.
anorexia, vomiting, reflux oesophagitis, decreased sweating, heat stroke, decreased lacrimation, mydriasis, tachycardia, arrhythmia, nightmares, restlessness, convulsion, intraocular hypertension and induction of glaucoma, paranoia, photosensitivity, erectile dysfunction.
zmanjšano solzenje, midriaza, tahikardija, aritmija, nočne more, nemir, konvulzije, intraokularna hipertenzija in indukcija glavkoma, paranoja, preobčutljivost za svetlobo, erektilna disfunkcija.
Gently washing the application site with warm water and a mild soap should remove any adhesive that remains on your skin after removal of the patch.
Po odstranitvi obliža nežno umivanje mesta nanosa s toplo vodo in blagim milom odstrani vse ostanke lepila na koži.